Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma

Yang,Yong; Lei,Tiantian; Du,Suya; Tong,Rongsheng; Wang,Hailian; Yang,Jiao; Huang,Juan; Sun,Minghan; Wang,Yi; Dong,Zhi

doi:10.3892/ijo.2018.4237

Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma

Authors:
- Yong Yang
- Tiantian Lei
- Suya Du
- Rongsheng Tong
- Hailian Wang
- Jiao Yang
- Juan Huang
- Minghan Sun
- Yi Wang
- Zhi Dong
View Affiliations

Affiliations: Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China, Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Institute of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Department of Pharmacy, Medical Center Hospital of Qionglai, Qionglai, Sichuan 611500, P.R. China, Department of Gynecology, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: January 4, 2018 https://doi.org/10.3892/ijo.2018.4237
Pages: 709-720
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma is the most malignant and lethal subtype brain tumors with high risk of recurrence and therapeutic resistance. Emerging evidence has indicated that glycogen synthesis kinase 3 (GSK3)β plays oncogenic roles in multiple tumor types; however, the underlying mechanisms remain largely unknown. It has also been demonstrated that p53 binding protein 1 (53BP1) plays a central role in DNA double-strand break (DSB) repair. This study aimed to reveal the significance of GSK3β translocation from the cytoplasm to the nucleus, and to determine whether GSK3β induces DNA DSB repair in the nuclei of glioblastoma cells via phospho-53BP1. By performing in vitro experiments, we found that GSK3β translocated from the cytoplasm to the nucleus, and it then bound to 53BP1 following exposure to IR (IR). In addition, 53BP1-mediated DNA DSB repair was observed to be abrogated by the inhibition of GSK3β. Further experiments on the phosphorylation site of 53BP1 by GSK3β revealed that the S/T-Q motif may play a critical role. Importantly, our in vivo and in vitro data clearly indicated that GSK3β induced the phosphorylation of 53BP1 at the Ser166 site. Moreover, brain tumor xenograft models revealed that following exposure to IR plus SB216763, a specific GSK3β inhibitor, tumor growth was markedly inhibited and the survival of mice markedly increased. Based on these results, we concluded that the phosphorylation of 53BP1 by GSK3β was indispensable for DNA DSB repair. Our study also suggested that the inhibition of GSK3β by SB216763 significantly inhibited the proliferation and induced the apoptosis of glioblastoma cells. Taken together, our data indicate that GSK3β, a key phosphorylation protein for 53BP1, may be a potential target for enhancing the sensitivity of glioblastoma cells to radiation.

View Figures

View References

1	Killock D: CNS cancer: Molecular classification of glioma. Nat Rev Clin Oncol. 12:5022015. View Article : Google Scholar : PubMed/NCBI
2	Debus J and Abdollahi A: For the next trick: New discoveries in radiobiology applied to glioblastoma. Am Soc Clin Oncol Educ Book. 2014:e95–e99. 2014. View Article : Google Scholar
3	Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR and Brown JM: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 120:694–705. 2010. View Article : Google Scholar : PubMed/NCBI
4	Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, et al German Glioma Network: Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 129:659–670. 2011. View Article : Google Scholar : PubMed/NCBI
5	Delfino KR, Serão NV, Southey BR and Rodriguez-Zas SL: Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics. 8:173–183. 2011.PubMed/NCBI
6	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
7	Panier S and Boulton SJ: Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 15:7–18. 2014. View Article : Google Scholar
8	Schultz LB, Chehab NH, Malikzay A and Halazonetis TD: p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol. 151:1381–1390. 2000. View Article : Google Scholar
9	Squatrito M, Vanoli F, Schultz N, Jasin M and Holland EC: 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. Cancer Res. 72:5250–5260. 2012. View Article : Google Scholar : PubMed/NCBI
10	Rappold I, Iwabuchi K, Date T and Chen J: Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 153:613–620. 2001. View Article : Google Scholar : PubMed/NCBI
11	Doble BW and Woodgett JR: GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186. 2003. View Article : Google Scholar : PubMed/NCBI
12	Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000. View Article : Google Scholar : PubMed/NCBI
13	Sugden PH, Fuller SJ, Weiss SC and Clerk A: Glycogen synthase kinase 3 (GSK3) in the heart: A point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 153(Suppl 1): S137–S153. 2008. View Article : Google Scholar : PubMed/NCBI
14	Gao C, Hölscher C, Liu Y and Li L: GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 23:1–11. 2011. View Article : Google Scholar
15	Kim L and Kimmel AR: GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev. 10:508–514. 2000. View Article : Google Scholar : PubMed/NCBI
16	Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumori-genesis and cancer chemotherapy. Cancer Lett. 273:194–200. 2009. View Article : Google Scholar
17	Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM and Boucher MJ: Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J Biol Chem. 290:5592–5605. 2015. View Article : Google Scholar : PubMed/NCBI
18	Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 334:1365–1373. 2005. View Article : Google Scholar : PubMed/NCBI
19	Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, et al: A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 8:1398–1406. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mulholland DJ, Dedhar S, Wu H and Nelson CC: PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene. 25:329–337. 2006. View Article : Google Scholar : PubMed/NCBI
21	Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, Hayashi Y, Hamada J and Minamoto T: Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clin Cancer Res. 15:887–897. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, et al: Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST and Billadeau DD: Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 12:5074–5081. 2006. View Article : Google Scholar : PubMed/NCBI
24	Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, Wang Z, Aldape KD, Xie K, Woodgett JR, et al: Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol. 18:954–966. 2016. View Article : Google Scholar : PubMed/NCBI
25	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
26	Boyé K, Pujol N, D Alves I, Chen YP, Daubon T, Lee YZ, Dedieu S, Constantin M, Bello L, Rossi M, et al: The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors. Nat Commun. 8:15712017. View Article : Google Scholar : PubMed/NCBI
27	Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, et al: Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 36:3037–3047. 2017. View Article : Google Scholar
28	Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P Jr, Hemmings BA, Merlo A and Lino MM: GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One. 4:e74432009. View Article : Google Scholar : PubMed/NCBI
29	Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J and Pollack IF: Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest. 85:1457–1470. 2005. View Article : Google Scholar : PubMed/NCBI
30	Bijur GN and Jope RS: Glycogen synthase kinase-3 β is highly activated in nuclei and mitochondria. Neuroreport. 14:2415–2419. 2003. View Article : Google Scholar : PubMed/NCBI
31	Williams RS, Williams JS and Tainer JA: Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol. 85:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
32	Jowsey P, Morrice NA, Hastie CJ, McLauchlan H, Toth R and Rouse J: Characterisation of the sites of DNA damage-induced 53BP1 phosphorylation catalysed by ATM and ATR. DNA Repair (Amst). 6:1536–1544. 2007. View Article : Google Scholar
33	Harding SM, Coackley C and Bristow RG: ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiother Oncol. 99:307–312. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102. 2004. View Article : Google Scholar : PubMed/NCBI
35	Wu D and Pan W: GSK3: A multifaceted kinase in Wnt signaling. Trends Biochem Sci. 35:161–168. 2010. View Article : Google Scholar :
36	Hur EM and Zhou FQ: GSK3 signalling in neural development. Nat Rev Neurosci. 11:539–551. 2010. View Article : Google Scholar : PubMed/NCBI
37	Abraham RT: Checkpoint signalling: Focusing on 53BP1. Nat Cell Biol. 4:E277–E279. 2002. View Article : Google Scholar : PubMed/NCBI
38	Ward IM, Minn K, van Deursen J and Chen J: p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 23:2556–2563. 2003. View Article : Google Scholar : PubMed/NCBI
39	Wang B, Matsuoka S, Carpenter PB and Elledge SJ: 53BP1, a mediator of the DNA damage checkpoint. Science. 298:1435–1438. 2002. View Article : Google Scholar : PubMed/NCBI
40	DiTullio RA Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J and Halazonetis TD: 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 4:998–1002. 2002. View Article : Google Scholar : PubMed/NCBI
41	Ward IM, Minn K, Jorda KG and Chen J: Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J Biol Chem. 278:19579–19582. 2003. View Article : Google Scholar : PubMed/NCBI
42	Anderson L, Henderson C and Adachi Y: Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol Cell Biol. 21:1719–1729. 2001. View Article : Google Scholar : PubMed/NCBI
43	Xia Z, Morales JC, Dunphy WG and Carpenter PB: Negative cell cycle regulation and DNA damage-inducible phosphorylation of the BRCT protein 53BP1. J Biol Chem. 276:2708–2718. 2001. View Article : Google Scholar